Compare Abeona Therapeutics Inc (ABEO) vs YieldMax AMZN Option Income Strategy ETF (AMZY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs YieldMax AMZN Option Income Strategy ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while YieldMax AMZN Option Income Strategy ETF trades at $10.68. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | AMZY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $16.61 |
52-Week Low | $4.17 | $10.26 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AMZY trades at $10.74, up 0.51% today, with a bearish technical signal from moving averages. The ETF generates high weekly dividends but faces scrutiny over net asset value erosion. Recent news highlights consistent distribution announcements alongside analyst downgrades citing structural risks in its synthetic option strategy relative to Amazon's performance.
The outlook is cautious due to inevitable NAV erosion despite high yield, with total returns lagging Amazon. Risks include amplified downside exposure and unsustainable payouts. Investors prioritizing income may find appeal, but long-term capital appreciation appears constrained by the fund's design.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →
